Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Alembic Pharma gains on getting USFDA's nod for Vardenafil Hydrochloride Orally Disintegrating Tablets

04-Jul2017

Alembic Pharma gains on getting USFDA's nod for Vardenafil Hydrochloride Orally Disintegrating Tablets

Alembic Pharmaceuticals is currently trading at Rs. 516.00, up by 1.20 points or 0.23% from its previous closing of Rs. 514.80 on the BSE.

The scrip opened at Rs. 515.80 and has touched a high and low of Rs. 519.00 and Rs. 509.00 respectively. So far 3156 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 492.25 on 27-Jun-2017.

Last one week high and low of the scrip stood at Rs. 529.95 and Rs. 492.25 respectively. The current market cap of the company is Rs. 9708.57 crore.

The promoters holding in the company stood at 72.68%, while institutions and non-institutions held 13.74% and 13.58% respectively.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vardenafil Hydrochloride Orally Disintegrating Tablets, 10mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) STAXYN Orally Disintegrating Tablets, 10mg, of Bayer Healthcare and is used under license by GlaxoSmithKline.

Vardenafil Hydrochloride Orally Disintegrating Tablets are indicated for the treatment of erectile dysfunction. Vardenafil Hydrochloride Orally Disintegrating Tablets have an estimated market size of $9.5 million for twelve months ending December 2016 according to IMS.

Alembic is currently in litigation with Bayer in District Court of Delaware and the launch of this product will depend on the outcome of litigation. The company now has a total of 59 ANDA approvals (52 final approvals and 7 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.


Related News

View all news

Birla Precision Technologies receives approval to issue of 6,07,005 Equity Shares

Birla Precision Technologies has received approval to issue of 6,07,005 Equity Shares at Rs 16.24 each on preferential basis to Zenith Dye intermediates. The Board of Directors has at its meeting held ......

Bajaj Finance strengthens on the bourses

Bajaj Finance is currently trading at Rs. 2656.30, up by 3.25 points or 0.12% from its previous closing of Rs. 2653.05 on the BSE.The scrip opened at Rs. 2659.95 and has touched a high and low of Rs. 2674.40......

Elgi Equipments surges on launching direct drive reciprocating air compressor

Elgi Equipments is currently trading at Rs. 252.00, up by 4.90 points or 1.98% from its previous closing of Rs. 247.10 on the BSE.The scrip opened at Rs. 251.75 and has touched a high and low of Rs. 252.00......

Top News

View all news

City Union Bank opens four new branches in Tamil Nadu

City Union Bank has opened four new branches in the state of Tamil Nadu on February 22, 2019. The bank has inaugurated 621th and 622nd branch at Nambiyur and Moolapalayam, respectively. The bank has also......

Syndicate Bank enters into partnership with Srei Equipment Finance

Syndicate Bank has entered into partnership with Srei Equipment Finance to jointly provide financing for construction and farm equipment. Under the arrangement, Syndicate Bank would leverage on its low-cost......

Tata Motors to supply 80 Electric buses to West Bengal Transport Corporation

Tata Motors will supply 80 Electric buses to the West Bengal Transport Corporation (WBTC). The company has already supplied 20 Ultra Electric 9/9m AC E-buses, with remaining 20 9/9m AC E-buses scheduled......